Article Sidebar
Published:
Aug 19, 2023DOI:
10.4314/tjpr.v22i7.4Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Total flavonoids of Rhizoma drynariae influence ferroptosis in osteoblasts via miR-205-5p/GPX4 axis
Abstract
Purpose: This research investigated the biological effects of total flavonoids of Rhizoma Drynariae (TFRD) on osteoporosis in mice.
Methods: Mice were subjected to bilateral ovariectomy (OVX) to generate the osteoporosis model used, which was then intragastrically administered TFRD daily at a dose of 75 mg/kg. Bone loss was examined histologically using H&E staining. Moreover, erastin-treated primary osteoblasts were used to further analyze the effect of TFRD on ferroptosis. Reactive oxygen species (ROS), ferrous iron level, and CCK-8 method were employed to determine the protective influence of TFRD against ferroptosis in erastin-treated osteoblasts. The relationship between microRNA-205-5p (miR-205-5p) and glutathione peroxidase 4 (GPX4) was determined using luciferase assay.
Results: TFRD treatment inhibited OVX-induced bone mass loss, downregulated ferrous ion content, and increased the level of GPX4 in vivo (p < 0.01). Besides, TFRD treatment inhibited erastin-induced increases in ROS level and ferrous iron level, and promoted cell viability in vitro (p < 0.01). Moreover, TFRD increased GPX4 protein expression level (p < 0.01). Results from gain and loss experiments showed that GPX4 increased cell viability, and reduced ferrous ion and ROS levels in erastin-induced osteoblasts (p < 0.01, p < 0.001, respectively). Furthermore, miR-205-5p directly targeted GPX4 and negatively regulated GPX4 expression (p < 0.01, p < 0.001, respectively). Upregulation of GPX4 reversed the effect of miR-205-5p overexpression on cell viability, and reduced ferrous iron level and ROS levels in osteoblasts significantly.
Conclusion: TFRD may serve as an inhibitor of osteoblast ferroptosis during osteoporosis formation by down-regulating the expression of miR-205-5p which directly targets GPX4 in mouse osteoblasts. These findings indicate the therapeutic potential and underlying mechanism of action of TFRD.
